Found 551 clinical trials
Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid Tumors
Ib: To evaluate the safety, tolerability and efficacy of OVV-01 injection combined with immune checkpoint inhibitors pembrolizumab (anti-PD-1 monoclonal antibody) or atezolizumab (anti-PD-L1
- 2 views
- 07 Apr, 2023
- 1 location
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV
- 0 views
- 23 Jun, 2021
- 1 location
NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors
NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in n=6 patients with solid tumors
- 0 views
- 25 May, 2022
- 1 location
Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM
of colorectal cancer patients. Rigofenib is one of the standard third-line treatments for advanced colorectal cancer, but has limited efficacy. Immune checkpoint inhibitors (PD-L1 monoclonal antibody
- 0 views
- 04 Oct, 2022
- 1 location
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
-CD38 monoclonal antibody.
- 5 views
- 04 Oct, 2022
- 6 locations
A Phase I, First-in-human, Multicenter, Open-label, Dose Escalation Followed by an Expansion Phase Clinical Study of KBA1412 Given as Monotherapy or in Combination With Pembrolizumab in Adults With Advanced Solid Malignant Tumors
The purpose of this trial is to assess the safety and efficacy of KBA1412, a patient derived, fully human, monoclonal antibody targeting CD9, in patients with advanced solid malignant tumors
- 0 views
- 28 Oct, 2022
- 2 locations
Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.
This study will examine whether the human monoclonal antibody, bezlotoxumab administered AFTER acute Clostridioides difficile (C.diff) has resolved, but during a period of subsequent antibiotic
- 0 views
- 29 Jun, 2022
- 1 location
A Clinical Study of MIL93 in Solid Tumors.
MIL93 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This is an open label Phase I study to evaluate safety, tolerability, pharmacokinetics and efficacy of
- 0 views
- 08 Apr, 2023
- 1 location
Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing
(recombinant humanized anti-IL-17A monoclonal antibody) Injection in patients with moderate to severe psoriasis.
- 0 views
- 10 May, 2022
- 10 locations
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
This is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant glioma at
- 0 views
- 04 Oct, 2022
- 1 location